Accuray (ARAY) Reports Q3 Loss, Tops Revenue Estimates
Accuray (ARAY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.06 per share a year ago.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up
Accuray delivers solid fiscal second-quarter results, witnessing growth in Product revenues and reduced operating expenses.
Accuray Incorporated (ARAY) Q2 2025 Earnings Call Transcript
Accuray Incorporated (NASDAQ:ARAY ) Q2 2025 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Brooks O'Neil - Lake Street Capital Markets Operator Good day, and welcome to the Accuray Fiscal 2025 Second Quarter Financial Results Conference Call. All participants will be in a listen-only mode.
Accuray (ARAY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
Accuray (ARAY) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.10 per share a year ago.
Accuray (ARAY) Shows Fast-paced Momentum But Is Still a Bargain Stock
Accuray (ARAY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions
Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.
Here's Why You Should Add Accuray Stock to Your Portfolio Now
ARAY's solid product demand and revenue growth raise optimism about the stock.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Accuray (ARAY)
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
5 Beaten-Down MedTech Stocks Set to Rebound in 2025
Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.
